Development of carvedilol-cyclodextrin inclusion complexes using fluid-bed granulation: a novel solid-state complexation alternative with technological advantages
Nenhuma Miniatura disponível
Data
2016
Título da Revista
ISSN da Revista
Título de Volume
Editor
Resumo
Objectives This study sought to evaluate the achievement of carvedilol (CARV)
inclusion complexes with modified cyclodextrins (HPbCD and HPcCD) using
fluid-bed granulation (FB).
Methods The solid complexes were produced using FB and spray drying (SD)
and were characterised by differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR), powder X-ray diffraction, SEM, flowability
and particle size analyses and in vitro dissolution.
Key findings The DSC, FTIR and powder X-ray diffraction findings suggested
successful CARV inclusion in the modified b- and c-cyclodextrins, which was
more evident in acidic media. The CARV dissolution rate was ~7-fold higher for
complexes with both cyclodextrins prepared using SD than for raw CARV. Complexes prepared with HPbCD using FB also resulted in a significant improvement
in dissolution rate (~5-fold) and presented superior flowability and larger particle
size.
Conclusions The findings suggested that FB is the best alternative for large-scale
production of solid dosage forms containing CARV. Additionally, the results suggest that HPcCD could be considered as another option for CARV complexation
because of its excellent performance in inclusion complex formation in the solid
state.
Descrição
Palavras-chave
Carvedilol, Hydroxypropyl-b-cyclodextrin, Hydroxypropyl-c-cyclodextrin, Solid-state inclusion complex
Citação
ALONSO, Ellen C. P. et al. Development of carvedilol-cyclodextrin inclusion complexes using fluid-bed granulation: a novel solid-state complexation alternative with technological advantage. Journal of Pharmacy and Pharmacology, [s. l.] v. 68, n. 10, p. 1299-1309, 2016. DOI: 10.1111/jphp.12601. Disponível em: https://academic.oup.com/jpp/article/68/10/1299/6128196. Acesso em: 30 nov. 2023.